Abstract:Key PointsCNS remyelination is the regenerative process by which myelin sheaths are restored to demyelinated axons. Unlike the poor regeneration that occurs following neuronal injury, remyelination can occur as a spontaneous and efficient process in experimental models and many clinical conditions.Although remyelination can occur in multiple sclerosis (MS; a widely occurring demyelinating disease), it often fails, leaving axons demyelinated and vulnerable to degeneration. Recent studies have revealed the importance of the myelin sheath for maintaining axonal integrity and hence the importance of promoting remyelination in diseases such as MS as an effective means of neuroprotection.Remyelination is mediated by a population of adult neural stem cells that are widely distributed throughout the CNS and that are commonly referred to as oligodendrocyte precursor cells (OPCs). These cells respond to demyelination by activation, proliferation, migration and finally differentiation into remyelinating oligodendrocytes; it is the last of these processes that is most likely to fail in MS and leave areas of demyelination containing oligodendrocyte-lineage cells that are unable to fully differentiate.Remyelination is governed by a complex interaction of environmental signals and cell-intrinsic mechanisms that are triggered by the inflammatory response to injury. This response therefore has a key role in initiating remyelination. The network of signals that is involved in remyelination shows high levels of redundancy.In theory, remyelination can be enhanced either by promoting endogenous remyelination or by transplanting myelinating cells. The first approach, which may have a pharmacological basis, is especially attractive for diseases such as MS in which remyelination occurs and will involve either the antagonism of negative regulatory pathways and/or the enhancement of positive regulatory pathways.Cell therapy (transplantation) approaches to remyelination are expected to be of particular benefit for genetic demyelinating diseases in which there is an inherent defect in the oligodendrocyte lineage. Recent studies have provided proof-of-principle that human cells can be used to remyelinate the entire CNS in laboratory animal models.

Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination

Stem Cells in Central Nervous System Diseases: Promising Therapeutic Strategies.

Cell-based remyelinating therapy in inflammatory demyelinating injury of the CNS

Remyelination in the CNS: from biology to therapy

[Neuroscience] Remyelination in the Central Nervous System

Strategies for myelin regeneration: lessons learned from development

Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches

Effect of glial cells on remyelination after spinal cord injury.

Astrocyte-Oligodendrocyte interaction regulates central nervous system regeneration

[Mechanisms Underlying Remyelination with Special Focus on Demyelination Models of Multiple Sclerosis].

Regenerative Capacity of Macrophages for Remyelination

Promoting peripheral myelin repair

Promoting Remyelination in Central Nervous System Diseases: Potentials and Prospects of Natural Products and Herbal Medicine

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Cell‐based experimental strategies for myelin repair in multiple sclerosis

The role and potential therapeutic targets of astrocytes in central nervous system demyelinating diseases

Remyelinating Drugs at a Crossroad: How to Improve Clinical Efficacy and Drug Screenings

Clinical implications of myelin regeneration in the central nervous system

Glial-restricted progenitor cells: a cure for diseased brain?

Rejuvenation of Regeneration in the Aging Central Nervous System.

Demyelinating processes in aging and stroke in the central nervous system and the prospect of treatment strategy